$208,38
-$0,61(-%0,29)
*Data last updated: 2026-04-19 13:07 (UTC+8)
As of 2026-04-19 13:07, AbbVie (ABBV) is priced at $208,38, with a total market cap of $368,55B, a P/E ratio of 96,26, and a dividend yield of %3,23. Today, the stock price fluctuated between $207,87 and $212,34. The current price is %0,24 above the day's low and %1,86 below the day's high, with a trading volume of 5,57M. Over the past 52 weeks, ABBV has traded between $176,57 to $244,81, and the current price is -%14,88 away from the 52-week high.
ABBV Key Stats
Yesterday's Close$208,99
Market Cap$368,55B
Volume5,57M
P/E Ratio96,26
Dividend Yield (TTM)%3,23
Dividend Amount$1,73
Diluted EPS (TTM)2,37
Net Income (FY)$4,22B
Revenue (FY)$61,16B
Earnings Date2026-04-29
EPS Estimate2,59
Revenue Estimate$14,71B
Shares Outstanding1,76B
Beta (1Y)0.364
Ex-Dividend Date2026-04-15
Dividend Payment Date2026-05-15
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
SectorHealthcare
IndustryDrug Manufacturers - General
CEORobert A. Michael
HeadquartersNorth Chicago,IL,US
Official Websitehttps://www.abbvie.com
Employees (FY)57,00K
Average Revenue (1Y)$1,07M
Net Income per Employee$74,14K
AbbVie (ABBV) FAQ
What's the stock price of AbbVie (ABBV) today?
x
AbbVie (ABBV) is currently trading at $208,38, with a 24h change of -%0,29. The 52-week trading range is $176,57–$244,81.
What are the 52-week high and low prices for AbbVie (ABBV)?
x
What is the price-to-earnings (P/E) ratio of AbbVie (ABBV)? What does it indicate?
x
What is the market cap of AbbVie (ABBV)?
x
What is the most recent quarterly earnings per share (EPS) for AbbVie (ABBV)?
x
Should you buy or sell AbbVie (ABBV) now?
x
What factors can affect the stock price of AbbVie (ABBV)?
x
How to buy AbbVie (ABBV) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.